摘要
目的:采用5/6肾切除方法建立慢性肾衰竭大鼠模型,观察抗纤灵对5/6肾切除大鼠肾组织中TGF-β/PI3k/Akt信号通路的影响。方法:将SD大鼠分为正常组、模型组(生理盐水)、治疗组(抗纤灵)各12只,除正常组外均采用5/6肾切除方法建立慢性肾衰竭大鼠模型,疗程2个月。应用生化、放射免疫法、western blot等技术,检测肾功能、24 h尿蛋白定量、肾脏病理,检测TGF-β/P13K/Akt信号通路蛋白表达。结果:实验结束时,与模型组相比较,抗纤灵组的血肌酐数值显著下降(P<0.01)、蛋白尿下降差异有统计学意义(P<0.05);病理MASSON染色:抗纤灵组肾小球肥大减弱,毛细血管基底膜增厚减轻,系膜基质明显减少,胶原纤维成分低于模型组;western blot检测,与模型组相比,抗纤灵组的p-Akt灰度比值显著下降。结论:抗纤灵方可能通过抑制TGF-β/PI3K/Akt信号通路,从而有效地降低5/6肾切除大鼠的血肌酐,减轻肾组织纤维化、改善肾功能、降低蛋白尿。
Objective: Replicate 5 /6 nephrectomy CRF rat's models to observe the effects on TGF- β / P13 K / Akt signal passage of experimental rats with "Kang Xian Ling Decoction". Methods: Divide 36 rats into three groups( normal group,model group with physiological saline,treatment group with the drug); then replicate 5 /6 nephrectomy CRF rat's models except normal group for 2 months; apply medical technology such as biochemical mensuration of blood and organization,Radioimmunoassay and Western blot to detect renal function and 24 h UPro,wrenal pathology and TGF- β / P13 K / Akt signal passage. Results: After experiment,compared with model group,serum creatinineresults of mode group dramatically reduced( P 0. 01),serum creatinine of treatment group increase obviously( P 0. 05),Pathology observation MASSON; compared with model group,Hypertrophy on glomerulus and basilar membrane on capillary vessel of treatment group has weakened. There has been an obvious decrease in mesentery stroma;collagenous fibre elements is lower than model group; During western blot examination,compared with model group,gray value of p-Akt in treatment group decline obviously. Conclusion: Chinese medicine "Kang Xian Ling Decoction"can significantly improve kidney function of 5 /6 nephrectomy CRF rats through reducing albuminuria and serum creatinine to protect renal function with inhibiting TGF- β / P13 K / Akt signal passage.
出处
《中国中西医结合肾病杂志》
2016年第6期480-483,I0001,共5页
Chinese Journal of Integrated Traditional and Western Nephrology
基金
上海市教育委员会科研创新项目(No.12YZ069)
上海市科学技术委员会科研计划项目(No.11ZR1437700)
国家自然科学基金资助项目(No.81173615)
国家临床重点专科
国家中医药管理局重点学科
上海市进一步加快中医药事业发展三年行动计划(2014年~2016年)建设项目(No.ZY3-LCPT-1-1006)